# Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP

> **NCT06727357** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **European Institute of Oncology** · enrollment: 38 (actual)

## Conditions studied

- Breast Cancer, Metastatic Breast Cancer

## Interventions

- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06727357
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-26
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06727357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06727357, "Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06727357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*